Ocrelizumab subcutaneous injection has demonstrated near-complete suppression of relapses and brain lesions in individuals with relapsing or primary progressive multiple sclerosis (MS), according to results from the phase 3 OCARINA II study. Treatment with ocrelizumab showed rapid and sustained B-cell depletion in the blood, and was generally well-tolerated.